Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Recruiting

Back to Hepatocellular Carcinoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong

Key details

Phase

Early testing

Sponsor

Hua Li

Enrollment target

~70 participants

Started

January 2024

Primary completion

November 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated July 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov

Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies — Stella